It doesn’t begin with pain or swelling. There are no warning signs — until it’s too late. By the time most patients are diagnosed, nearly 90% of their kidney function is already lost. A recent study ...
Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna. The agreement gives Merck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback